Tiziana Life Sciences – Clinical pipeline update, resolutions seeking shareholder authority to issue new shares for cash & approval of proposed option grant April 21, 2020 – Posted in: Tiziana Life Sciences (TILS)

London, New York 21 April 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the “Company” or “Tiziana”), the U.S. and U.K. biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, today announces that it has convened a general meeting (the “GM”) to consider proposals to take increased authorities to allot shares; consider the replacement of share option awards and to adopt…

Continue reading

Tiziana Life Sciences #TILS – Update Re: Block Listing Application April 15, 2020 – Posted in: Tiziana Life Sciences (TILS)

London / New York 15 April 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the “Company” or “Tiziana”), the U.S. and U.K. biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, announces further to the announcement made today regarding the Block Listing Application and “At The Market” Sales Agreement, an updated application has been made to AIM for a block admission…

Continue reading

Tiziana Life Sciences #TILS – Block Listing Application and “At The Market” Sales Agreement – Posted in: Tiziana Life Sciences (TILS)

London / New York 15 April 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the “Company” or “Tiziana”), the U.S. and U.K. biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, today announces that that it has entered into an “At the Market” or “ATM” Sales Agreement with Think Equity (a division of Fordham Financial Management, Inc.) to raise up to…

Continue reading

Tiziana Life Sciences #TILS – Develops Novel Investigational Treatment For Patients Infected with COVID-19 April 9, 2020 – Posted in: Tiziana Life Sciences (TILS)

New York/London — April 9,  2020 – Tiziana Life Sciences plc (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for inflammatory and autoimmune diseases, announced today that it has developed investigational new technology to  treat COVID-19 infections, which consists of direct delivery of anti-IL-6 receptor (anti-IL-6R) monoclonal antibodies (mAbs) into the lungs using a handheld inhaler or nebulizer. Development of this novel technology is a step forward toward expediting  development…

Continue reading

Tiziana Life Sciences #TILS – Announces Closing of Offering and Resulting Total Voting Rights March 16, 2020 – Posted in: Tiziana Life Sciences (TILS)

London, New York 16 March 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the “Company” or “Tiziana”), a U.S. and U.K. biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, today announces the closing of its underwritten follow-on public offering (the “Offering”) of American Depositary Shares (“ADSs”) on the NASDAQ Global Market. Tiziana  issued 3,333,333 ADSs (representing 16,666,665 new ordinary shares…

Continue reading

Alan Green & Sarah Lowther discuss the market crash, lessons from China, plus an array of stocks including Tiziana Life #TILS & Open Orphan #ORPH on the Total Market Solutions podcast March 15, 2020 – Posted in: Open Orphan (ORPH), Tiziana Life Sciences (TILS)

Friday The 13th & The Weekend Podcast Alan Green Joins Sarah Lowther To Talk All Things Markets During this weekend podcast, and in the wake of a colossal fall, we look at markets which ended the week on Friday the 13th, so far we’ve witnessed an emergency rate cut by the bank of England as the FTSE had its worst day in 33yrs. Alan Green shares some insight on the most recent events surrounding Corona…

Continue reading